|
AU2016202592A1
|
|
Biomarkers for diagnosing multiple sclerosis, and methods thereof
|
|
AU2015200060A1
|
|
Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
|
|
AU2014201707A1
|
|
Methods for the treatment of Senile Dementia of the Alzheimer's Type
|
|
AU2013273746A1
|
|
Methods for the diagnosis of dementia and other neurological disorders
|
|
AU2013201305A1
|
|
Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin E-related metabolites
|
|
AU2013200748A1
|
|
Biomarkers for diagnosing multiple sclerosis, and methods thereof
|
|
US2014323749A1
|
|
Methods for the synthesis of 13C labeled plasmalogen
|
|
US2014309464A1
|
|
Methods for the synthesis of 13C labeled iodotridecane and use as a reference standard
|
|
WO2013071411A1
|
|
Methods for the synthesis of 13c labeled dha and use as a reference standard
|
|
AU2012231682A1
|
|
Method for the synthesis of DHA
|
|
CA2774869A1
|
|
Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
|
|
CA2768086A1
|
|
Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
|
|
MX2012001209A
|
|
Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis.
|
|
TW201034662A
|
|
Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
|
|
AU2008280806A1
|
|
Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
|
|
EP2145181A1
|
|
Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging
|
|
CN101932934A
|
|
Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states
|
|
US2008308723A1
|
|
Method of non-targeted complex sample analysis
|
|
AU2007346587A1
|
|
Methods for the treatment of Senile Dementia of the Alzheimer's Type
|
|
US2010062472A1
|
|
Biomarkers for diagnosing multiple sclerosis, and methods thereof
|
